Analytical Data
-
Gene name
BXDC5
- Application
-
Alternative Names
RPF1; BXDC5; Ribosome production factor 1; Brix domain-containing Protein 5; Ribosome biogenesis Protein RPF1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H9Y2
-
Expression Region
1-349aa
-
AA Sequence
MAKAGDKSSS SGKKSLKRKA AAEELQEAAG AGDGATENGV QPPKAAAFPP GFSISEIKNK QRRHLMFTRW KQQQRKEKLA AKKKLKKERE ALGDKAPPKP VPKTIDNQRV YDETTVDPND EEVAYDEATD EFASYFNKQT SPKILITTSD RPHGRTVRLC EQLSTVIPNS HVYYRRGLAL KKIIPQCIAR DFTDLIVINE DRKTPNGLIL SHLPNGPTAH FKMSSVRLRK EIKRRGKDPT EHIPEIILNN FTTRLGHSIG RMFASLFPHN PQFIGRQVAT FHNQRDYIFF RFHRYIFRSE KKVGIQELGP RFTLKLRSLQ KGTFDSKYGE YEWVHKPREM DTSRRKFHL
-
Molecular Weight
40.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BXDC5 is a protein that has garnered significant attention in the field of biotechnology and pharmaceutical research due to its potential roles in immune modulation and disease intervention. Initially identified through genomic studies focused on immune-related genes, BXDC5 is part of a larger family of proteins involved in the regulation of immune responses, particularly in the context of autoimmune diseases and cancer. The structural features of BXDC5 suggest that it may interact with specific receptors on immune cells, thereby influencing their activation and function. Research has indicated that recombinant forms of BXDC5 can enhance the proliferation and activation of T-cells and other immune effector cells, making it a candidate for therapeutic applications. Moreover, studies are exploring its potential as a biomarker for diseases where immune dysregulation is a hallmark. Ongoing investigations aim to elucidate the precise mechanisms by which BXDC5 exerts its effects, which could pave the way for innovative strategies in immunotherapy. As our understanding of this protein advances, its implications for enhancing vaccine responses and developing new immunotherapeutic agents may revolutionize treatment approaches for various immune-related disorders.
